Answers are grounded in this paper and cite their sources.
• Current Knowledge Gap: Elderly patients (≥70 years) with ductal carcinoma in situ (DCIS) represent a distinct population, yet existing prognostic models lack specific validation, and the survival benefit of adjuvant radiotherapy remains uncertain, especially in hormone receptor-negative disease. • Novel Prognostic Tool: We developed and validated the first cancer-specific survival (CSS) nomogram and risk stratification system specifically tailored for elderly (≥70 years) DCIS patients treated with lumpectomy. • Informed Radiotherapy Decision: Adjuvant radiotherapy was associated with a significant CSS benefit specifically in hormone receptor-negative subgroups, providing crucial evidence to guide treatment selection in this demographic. • Clinical Translation: This nomogram offers clinicians a practical, individualized tool for prognosis assessment and therapeutic planning, facilitating a more personalized management strategy. • Future Implications: The findings underscore the necessity of age-specific prognostic models in DCIS and suggest that future research should focus on age-related biological and clinical differences. To develop and validate a prognostic nomogram to predict cancer-specific survival (CSS) in elderly patients with ductal carcinoma in situ (DCIS) following breast-conserving surgery (BCS). Data from the SEER database (2000–2019) were used, comprising 40,502 eligible patients who were randomly assigned to training and validation cohorts. Cox proportional hazards and Fine-Gray competing risks regression models were employed. A nomogram was constructed and evaluated using time-dependent C-index, calibration curves, and decision curve analysis. Risk stratification and subgroup analyses were conducted. Multivariable analysis identified older age (≥80 years; HR 1.85, 95% CI 1.53–2.24), hormone receptor negativity (HR 1.33, 95% CI 1.04–1.69), and omission of radiotherapy (HR 1.34, 95% CI 1.11–1.61) as independent predictors of worse CSS. The nomogram demonstrated moderate discriminative ability, with time-dependent C-indices of 0.606 (training) and 0.659 (validation). Calibration and decision curve analysis demonstrated favorable clinical utility. Subgroup analyses indicated a significant CSS benefit from radiotherapy among hormone receptor-negative patients across all age groups (70–79: HR 0.349, p < 0.001; ≥80: HR 0.375, p = 0.045). We developed and validated a nomogram that integrates age, hormone receptor status, and radiotherapy use to predict CSS in older patients with DCIS following breast-conserving surgery. This tool could aid in identifying a high-risk patients, particularly those with hormone receptor-negative disease, who may derive significant survival benefit from adjuvant radiotherapy.
No takes yet. Share an insight, caveat, or question.
Hongxia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: